ArticleMicrobiology spectrum2022
Superinfection with SARS-CoV-2 Has Deleterious Effects on Mycobacterium bovis BCG Immunity and Promotes Dissemination of Mycobacterium tuberculosis.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Review
- Crosstalk betweenFrontiers in immunology · 2026Article
- BLV coinfection impairs immunity and diagnostics in bovine tuberculosis.Scientific reports · 2025Article
- Mycobacterium tuberculosis growth inhibition by peripheral blood mononuclear cells from household contacts is not affected by previous SARS-CoV-2 infection.Gates open research · 2025Article
- The impact of mycobacteria-induced trained immunity on SARS-CoV-2 vaccine responses.Frontiers in immunology · 2025Article
- Unmasking the hidden impact of viruses on tuberculosis risk.Trends in immunology · 2024Review
- Neuropathological lesions in intravenous BCG-stimulated K18-hACE2 mice challenged with SARS-CoV-2.Veterinary research · 2024Article
- Protective interplay:Frontiers in immunology · 2024Article
- Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2.Nature communications · 2023Article
- Tackling Drug-Resistant Tuberculosis: New Challenges from the Old PathogenMicroorganisms · 2023Review
- Review
- Discovering common pathogenetic processes between COVID-19 and tuberculosis by bioinformatics and system biology approach.Frontiers in cellular and infection microbiology · 2023Article
- Nitrogen metabolism in mycobacteria: the key genes and targeted antimicrobials.Frontiers in microbiology · 2023Review
- Protective RNA nanovaccines againstFrontiers in immunology · 2023Article
- Suppressive myeloid cells in SARS-CoV-2 andFrontiers in immunology · 2023Article
- Animal models for COVID-19 and tuberculosis.Frontiers in immunology · 2023Review
- Co-infection of mice with SARS-CoV-2 andFrontiers in immunology · 2023Article
- BCG mediated protection of the lung against experimental SARS-CoV-2 infection.Frontiers in immunology · 2023Review
- Initial immune response after exposure toFrontiers in immunology · 2023Review
- Mouse Models forPathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An estimated one-third of the world's population is infected with Mycobacterium tuberculosis, with the majority being vaccinated with Mycobacterium bovis BCG. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a threat, and we must understand how SARS-CoV-2 can modulate both BCG immunity and tuberculosis pathogenesis. Interestingly, neither BCG vaccination nor tuberculosis infection resulted in differences in clinical outcomes associated with SARS-CoV-2 in transgenic mice. Surprisingly, earlier M. tuberculosis infection resulted in lower SARS-CoV-2 viral loads, mediated by the heightened immune microenvironment of the murine lungs, unlike vaccination with BCG, which had no impact. In contrast, M. tuberculosis-infected tissues had increased bacterial loads and decreased histiocytic inflammation in the lungs following SARS-CoV-2 superinfection. SARS-CoV-2 modulated BCG-induced type 17 responses while decreasing type 1 and increasing type 2 cytokines in M. tuberculosis-infected mice. These findings challenge initial findings of BCG's positive impact on SARS-CoV-2 infection and suggest potential ramifications for M. tuberculosis reactivation upon SARS-CoV-2 superinfection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.